EUVIMEDEUVIMED entdecken
VergleichsstudieNetzwerk-Metaanalyse

Bayesian Indirect Comparison and Cost-Effectiveness of Sacituzumab Govitecan Versus Sacituzumab Tirumotecan in Metastatic Triple-Negative Breast Cancer

Yamin Shu, Ying Tang, Yiling Ding, Wenting Zhang, Qilin Zhang

Value in Health · 2026-08 · 29 (8) · 1385-1394

DOI: 10.1016/j.jval.2026.02.004 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Value in Health, 2026-08. Verfasst von Yamin Shu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Antibodies, Monoclonal, Humanized, Immunoconjugates, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Chinese Pharmaceutical Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Sacituzumab govitecan (SG) and sacituzumab tirumotecan (sac-TMT) are 2 approved antibody-drug conjugates for metastatic triple-negative breast cancer but lack direct comparison. Given their similar indications and high costs, an indirect cost-effectiveness analysis is essential to inform pricing and reimbursement decisions from the perspective of the Chinese healthcare system. METHODS: A partitioned survival model using Bayesian network meta-analysis and flexible parametric modeling estimated long-term survival, quality-adjusted life-years (QALYs), and costs. Participants were derived from the ASCENT and OptiTROP-Breast01 randomized controlled trials. Key outcomes included time-varying hazard ratio, life-years, costs, incremental cost-effectiveness ratio (ICER), incremental net health benefit, and incremental net monetary benefit. Multiple sensitivity and scenario analyses tested model robustness. RESULTS: In the base-case analysis, SG yielded 0.095 additional QALYs compared with sac-TMT at an incremental cost of $68 266, resulting in an ICER of $719 726 per QALY and an incremental net monetary benefit of -$64 400. Sensitivity analyses identified SG price and model time horizon as key drivers of ICER. In all plausible scenarios, SG remained not cost-effective versus sac-TMT. Probabilistic results showed a 0% probability of cost-effectiveness at a willingness-to-pay threshold of $40 763 per QALY. Scenario analysis confirmed the robustness of findings across assumptions on time horizon, utility, wastage, and discounting. CONCLUSIONS: SG showed slightly greater health gains but much higher costs than sac-TMT, leading to poor cost-effectiveness at current prices. Given the high substitutability between antibody-drug conjugates in metastatic triple-negative breast cancer, indirect comparisons with economic modeling can help guide payer decisions and pricing negotiations when head-to-head data are lacking.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsAntibodies, Monoclonal, HumanizedImmunoconjugatesAntineoplastic AgentsHumansCost-Benefit AnalysisCost-Effectiveness AnalysisBayes TheoremFemaleQuality-Adjusted Life YearsRandomized Controlled Trials as TopicCamptothecin

Stichwörter der Autor:innen

ADCsBayesiancost-effectivenessmTNBCtime-varying hazard ratio

Substanzen

sacituzumab govitecanAntibodies, Monoclonal, HumanizedImmunoconjugatesAntineoplastic AgentsCamptothecin

Autor:innen und Institutionen

  • Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Electronic address: wenting@hust.edu.cn.
  • Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Electronic address: qilinzhang88@163.com.

Förderung

  • National Natural Science Foundation of China
  • Chinese Pharmaceutical Association

Zitieren

APA

Shu, Y., Tang, Y., Ding, Y., Zhang, W., & Zhang, Q. (2026). Bayesian Indirect Comparison and Cost-Effectiveness of Sacituzumab Govitecan Versus Sacituzumab Tirumotecan in Metastatic Triple-Negative Breast Cancer. Value in Health, 29(8), 1385-1394. https://doi.org/10.1016/j.jval.2026.02.004

Vancouver

Shu Y, Tang Y, Ding Y, Zhang W, Zhang Q. Bayesian Indirect Comparison and Cost-Effectiveness of Sacituzumab Govitecan Versus Sacituzumab Tirumotecan in Metastatic Triple-Negative Breast Cancer. Value in Health. 2026;29(8):1385-1394. doi:10.1016/j.jval.2026.02.004

BibTeX
@article{Shu2026,
  author = {Shu, Yamin and Tang, Ying and Ding, Yiling and Zhang, Wenting and Zhang, Qilin},
  title = {Bayesian Indirect Comparison and Cost-Effectiveness of Sacituzumab Govitecan Versus Sacituzumab Tirumotecan in Metastatic Triple-Negative Breast Cancer},
  journal = {Value in Health},
  year = {2026},
  volume = {29},
  number = {8},
  pages = {1385--1394},
  doi = {10.1016/j.jval.2026.02.004}
}
Kostenlos starten →